MY193694A - Membrane-adherent self-assembled systems for treatment of ocular disorders - Google Patents
Membrane-adherent self-assembled systems for treatment of ocular disordersInfo
- Publication number
- MY193694A MY193694A MYPI2016703941A MYPI2016703941A MY193694A MY 193694 A MY193694 A MY 193694A MY PI2016703941 A MYPI2016703941 A MY PI2016703941A MY PI2016703941 A MYPI2016703941 A MY PI2016703941A MY 193694 A MY193694 A MY 193694A
- Authority
- MY
- Malaysia
- Prior art keywords
- delivery system
- drug delivery
- membrane
- treatment
- ocular disorders
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title abstract 2
- 238000012377 drug delivery Methods 0.000 abstract 4
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003232 mucoadhesive effect Effects 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 231100000344 non-irritating Toxicity 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987012P | 2014-05-01 | 2014-05-01 | |
| PCT/US2015/028748 WO2015168523A1 (en) | 2014-05-01 | 2015-05-01 | Membrane-adherent self-assembled systems for treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY193694A true MY193694A (en) | 2022-10-25 |
Family
ID=54359368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2016703941A MY193694A (en) | 2014-05-01 | 2015-05-01 | Membrane-adherent self-assembled systems for treatment of ocular disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9901544B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3137481B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6452725B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101890503B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106459137B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015252908B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2946373C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2924768T3 (cg-RX-API-DMAC7.html) |
| MY (1) | MY193694A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ725028A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201608729RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015168523A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3266446B1 (en) * | 2016-07-07 | 2018-11-21 | Laboratorios SALVAT, S.A. | Ophthalmic composition comprising castor oil and medium chain triglyceride |
| JPWO2018230713A1 (ja) * | 2017-06-16 | 2020-04-16 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
| US11433090B2 (en) | 2017-06-16 | 2022-09-06 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
| EP3643297A4 (en) * | 2017-06-22 | 2021-03-17 | Yonsung Fine Chemical Co., Ltd. | OPHTHALMIC COMPOSITION FOR THE TREATMENT OF GLAUCOMA |
| US11129862B2 (en) | 2017-08-30 | 2021-09-28 | Johnson & Johnson Consumer Inc. | Ophthalmic compositions |
| WO2019043169A1 (en) * | 2017-09-01 | 2019-03-07 | Murray & Poole Enterprises, Ltd | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS |
| JP7056480B2 (ja) * | 2017-09-08 | 2022-04-19 | ライオン株式会社 | 眼科用組成物及び涙液油層安定化剤 |
| CN109316440B (zh) * | 2018-09-29 | 2020-12-29 | 华中科技大学 | 一种温敏性液晶纳米水凝胶及其制备方法与应用 |
| DK3870226T3 (da) * | 2018-10-24 | 2023-09-18 | Ferring Bv | Mukoadhæsive farmaceutiske sammensætninger af kortikosteroider |
| GB201818043D0 (en) * | 2018-11-05 | 2018-12-19 | Waterford Institute Of Tech | Artifical Tears |
| WO2021234548A1 (en) * | 2020-05-18 | 2021-11-25 | Max Biology Co. Ltd. | Lipid-polymer compositions and methods of use |
| US11382910B2 (en) * | 2020-08-26 | 2022-07-12 | Somerset Therapeutics, Llc. | Loteprednol and moxifloxacin compositions and methods |
| US12102632B2 (en) | 2020-08-26 | 2024-10-01 | Somerset Therapeutics, Llc | Quinolone dispersions |
| AU2021360121A1 (en) * | 2020-10-13 | 2023-06-22 | University Of South Australia | Antimicrobial compositions and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716830B2 (en) * | 1998-09-30 | 2004-04-06 | Alcon, Inc. | Ophthalmic antibiotic compositions containing moxifloxacin |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| JP4049216B2 (ja) * | 2003-05-09 | 2008-02-20 | ポーラ化成工業株式会社 | 液晶構造を有する製剤 |
| US20070020299A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20050235740A1 (en) * | 2004-04-27 | 2005-10-27 | Guido Desie | Method to improve the quality of dispersion formulations |
| CN101005828B (zh) * | 2004-06-17 | 2012-01-11 | 维尔恩公司 | 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物 |
| US20080145430A1 (en) * | 2004-12-08 | 2008-06-19 | Santipharp Panmai | Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor |
| CN101137369A (zh) * | 2005-02-09 | 2008-03-05 | 马库赛特公司 | 用于眼治疗的制剂 |
| US8906392B2 (en) * | 2005-12-16 | 2014-12-09 | University Of Kansas | Nanocluster compositions and methods |
| WO2008011836A2 (es) * | 2006-07-25 | 2008-01-31 | Osmotica Corp. | Soluciones oftálmicas |
| JP2010064995A (ja) * | 2008-09-12 | 2010-03-25 | Nikko Chemical Co Ltd | 外用消炎鎮痛剤組成物 |
| EP2518040B1 (en) * | 2009-12-25 | 2018-10-31 | Farnex Incorporated | Low-viscosity liquid-crystal compound |
| CN101773670A (zh) * | 2009-12-29 | 2010-07-14 | 中山大学 | 一种液晶药物载体 |
| JP2012017318A (ja) * | 2010-06-07 | 2012-01-26 | Nikko Chemical Co Ltd | 液晶及びそれを含有する皮膚外用剤 |
| US8772273B2 (en) * | 2011-10-04 | 2014-07-08 | Quretino Therapeutics, Inc. | Formulations and uses of retinoic acid receptor selective agonists |
| NZ728721A (en) * | 2012-05-03 | 2018-05-25 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| EP3517541B1 (en) * | 2012-05-08 | 2020-07-15 | Nicox Ophthalmics, Inc. | Polymorphic form of fluticasone propionate |
-
2015
- 2015-05-01 MY MYPI2016703941A patent/MY193694A/en unknown
- 2015-05-01 KR KR1020167030513A patent/KR101890503B1/ko active Active
- 2015-05-01 NZ NZ725028A patent/NZ725028A/en unknown
- 2015-05-01 EP EP15785661.8A patent/EP3137481B1/en active Active
- 2015-05-01 JP JP2016565482A patent/JP6452725B2/ja active Active
- 2015-05-01 CA CA2946373A patent/CA2946373C/en active Active
- 2015-05-01 WO PCT/US2015/028748 patent/WO2015168523A1/en not_active Ceased
- 2015-05-01 CN CN201580019868.9A patent/CN106459137B/zh active Active
- 2015-05-01 SG SG11201608729RA patent/SG11201608729RA/en unknown
- 2015-05-01 ES ES15785661T patent/ES2924768T3/es active Active
- 2015-05-01 US US15/308,000 patent/US9901544B2/en active Active
- 2015-05-01 AU AU2015252908A patent/AU2015252908B2/en active Active
-
2018
- 2018-02-27 US US15/906,352 patent/US10603273B2/en active Active
- 2018-03-06 AU AU2018201596A patent/AU2018201596B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2946373A1 (en) | 2015-11-05 |
| JP6452725B2 (ja) | 2019-01-16 |
| AU2015252908A1 (en) | 2016-10-27 |
| AU2018201596A1 (en) | 2018-03-29 |
| US10603273B2 (en) | 2020-03-31 |
| US20180185275A1 (en) | 2018-07-05 |
| JP2017514843A (ja) | 2017-06-08 |
| US20170049697A1 (en) | 2017-02-23 |
| KR20160147784A (ko) | 2016-12-23 |
| AU2015252908B2 (en) | 2017-12-07 |
| ES2924768T3 (es) | 2022-10-10 |
| US9901544B2 (en) | 2018-02-27 |
| EP3137481B1 (en) | 2022-07-06 |
| WO2015168523A1 (en) | 2015-11-05 |
| CA2946373C (en) | 2018-07-31 |
| KR101890503B1 (ko) | 2018-08-21 |
| CN106459137A (zh) | 2017-02-22 |
| EP3137481A1 (en) | 2017-03-08 |
| CN106459137B (zh) | 2019-04-12 |
| EP3137481A4 (en) | 2017-12-27 |
| AU2018201596B2 (en) | 2020-02-06 |
| NZ725028A (en) | 2019-01-25 |
| SG11201608729RA (en) | 2016-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY193694A (en) | Membrane-adherent self-assembled systems for treatment of ocular disorders | |
| MX354210B (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| PH12017502155A1 (en) | Formation of cyclosporin a/cyclodextrin nanoparticles | |
| MY191380A (en) | Stabilized fixed dose drug composition having mometasone and olopatadine | |
| MX370953B (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| WO2014184576A3 (en) | Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain | |
| HK1217092A1 (zh) | 治疗性化合物及其用途 | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
| MX2015011905A (es) | Uso de levocetirizina y montelukast en el tratamiento de la vasculitis. | |
| ZA201704327B (en) | Methods and compositions for treating brain diseases | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| EP4420722A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| WO2015008169A3 (en) | Device, system and method for delivery of a long-acting drug | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| PH12017500538A1 (en) | Inhalation device | |
| MX2016011706A (es) | Formulaciones de progesterona. | |
| TR201903234T4 (tr) | Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti. | |
| MX2016013889A (es) | Medicamento. | |
| PH12018502195A1 (en) | Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases | |
| NZ740627A (en) | Oral suspension for treating eosinophilic esophagitis | |
| EA201692163A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом | |
| UA96488U (uk) | Спосіб лікування порушень гемоваскулярного гемостазу у хворих на ішемічну хворобу серця | |
| BR112016027104A2 (pt) | nanopartícula terapêutica, composição farmacêutica, e, método de tratamento de hipertensão |